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Abstract 
Background: Dengue Expert Advisory Group 
(DEAG) guidelines are used for management of 
dengue patients in our scenario. It was observed in 
last consecutive dengue epidemics at Rawalpindi 
that some of the dengue shock syndrome (DSS) 
patients don’t improve unless modifications in 
DEAG guidelines are made. This study was 
conducted to evaluate modified DEAG management 
guidelines in DSS patients with decompensated 
shock who were not improving with treatment based 
on standard DEAG guidelines. 
Methods: This quasi experimental study was 
conducted at Dengue Units of Hospitals attached 
with Rawalpindi Medical College during 
Rawalpindi dengue epidemic 2015. Dengue Shock 
Syndrome (DSS) patients who were not improving 
with DEAG guidelines based treatment, were 
managed as per modified treatment plan i.e., 
continuing with colloid or blood depending on HCT 
in tapering way for initial few hours after 
hemodynamic stabilization is achieved. Outcome 
was recorded in terms of improvement/recovery and 
mortality. Poor outcome (mortality was correlated 
with mean age, gender, primary or secondary dengue 
infection, presence of additional illnesses and mean 
duration of hospital stay by Chi2 and t test wherever 
relevant. 
Results: Seventeen patients were included in the 
study. 64.7% were female. Mean patient age was 
31.29±9.56 years. Thirteen patients (76.47%) 
recovered and were discharged. Four patients 
(23.52%) expired. Poor outcome had statistically 
significant association with presence of additional 
illnesses and shorter duration of hospital stay (p 
value <0.05).  
Conclusion: Modification in DEAG treatment plan 
lead to better outcome in majority of DSS patients 
who did not improve with DEAG standard 
management. 
Key Words: Dengue shock syndrome,Guidelines, 
Mortality 
Introduction 
Dengue has emerged as important healthcare issue in 
Pakistan during last two decades.1,2,3Hyper-immune 
response and plasma leakage are hallmarks of 
complicated version of dengue infection which is 
termed as dengue hemorrhagic fever (DHF).4,5Dengue 
shock syndrome (DSS) is worst form of dengue 
infection.4,5 It occurs when shock develops in DHF 
scenario. 
Plasma leakage leading to depletion of intravascular 
volume is hallmark of DHF/DSS. Fluid resuscitation is 
thus main stay of therapy in DHF/DSS 
management.8Preventing shock and overload along 
with maintenance of hemodynamics are goals of 
DHF/DSS treatment. Dengue patients in Punjab 
province of Pakistan are managed according to the 
guidelines issued by Dengue Expert Advisory Group 
(DEAG).4On the basis of these guidelines,fluid quota is 
calculated for every DHF/DSS patient during critical 
phase in order to achieve the desired goals of 
DHF/DSS management. It is calculated by formula: 
maintenance + 5% of body weight.  For an adult 
≥50Kg, it is 4600 ml.4 
Rawalpindi city is continuously been hit by dengue 
epidemics for last few years. 339, 802, and 1468 
DHF/DSS patients were managed at 3 main public 
hospitals (Holy Family Hospital, Benazir Bhutto 
Hospital, and DHQ Teaching Hospital)of Rawalpindi 
that are attached with Rawalpindi Medical College 
during the years 2013, 2014, and 2015respectively. 
Difficult situations were encountered during 
management of DHF/DSS patients while using DEAG 
based guidelines/algorithms. In some of the DSS 
patients either patients remained in shock or went into 
shock again while complying with DEAG based 
treatment. We have noted in the last years that DSS  
patients improve following stabilization with colloid 
or blood bolus, if colloid or blood are continued in 
tapering way for some time instead of shuffling to 
crystalloid at once per DEAG guidelines. Such 
modification of DEAG guidelines lead to good 
outcome. We thus in this year devised algorithm for 
managing DSS patients who remained in shock despite 
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DEAG guideline based management(Figure 1).This 
study was conducted to evaluate these modified 
guidelines in DSS patients with decompensated shock 
who were not improving with treatment based on 
standard DEAG guidelines. 
 
Patients and Methods 
This quasi experimental study was conducted in 
Dengue Units of hospitals attached with Rawalpindi 
Medical College, Rawalpindi during the Rawalpindi 
dengue epidemic 2015 (1st August to 20th December 
2015). Approval was taken in this regard from Ethical 
& Research Committee of Rawalpindi Medical 
College. All adult patients diagnosed as DSS who were 
not improving with management as per DEAG 
guidelines were included after informed consent. DSS 
patients who suffered from co-infections (malaria, 
enteric fever, acute hepatitis),neoplastic disorders, 
complicated diabetes, cardiac, and renal failure etc. 
were excluded.   
DSS diagnosis: DHF/DSS diagnosis was based on 
DEAG criteria. DHF was diagnosed when a confirmed 
case of dengue infection and hemorrhagic tendency 
developed plasma leak due to increased capillary 
permeability.4,5 If a DHF patient developed 
hypotension for age along with cold clammy skin and 
restlessness, he was diagnosed 
to be suffering from DSS.4,5 
Not improving with DEAG 
based management: It meant 
that hemodynamic stability 
was not achieved despite 
complying with management 
based on DEAG guidelines 
i.e., patients continued to 
have circulatory failure 
manifested by tachycardia, 
bare to non-palpable pulse, 
<20 mm Hg pulse pressure to 
un-recordable blood pressure, 
and persistently decreased 
urinary output 
<0.25ml/Kg/hour.4 
Guidelines based treatment: 
All patients were managed at 
High Dependency Units or 
Intensive Care Units. Treatment 
was instituted according to 
algorithm given in Figure 1. 
Each patient was monitored per 
DEAG monitoring sheets for 
DSS.4 Additional illnesses/co-
morbidities, complications of the disease and 
treatment modalities were sought and managed 
accordingly. 
Outcome: Outcome was divided into 
improved/recovered and expired. 
Data collection and analysis: A specially designed 
performa was used with focus on age, gender, primary 
or secondary dengue infection, presence or absence of 
additional illnesses, duration of hospitalization and 
outcome.  
Data analysis was performed employing Statistical 
Package for Social Sciences (SPSS). Frequency and 
percentage were calculated for gender, primary or 
secondary dengue infection, presence or absence of 
additional illnesses, and outcome. For age and 
duration of hospital stay mean ± SD was calculated. 
Outcome based comparison of categorical and 
continuous variables were done using Chi2 and t test 
respectively. 
 
Results 
Seventeen patients were included in the study. Mean 
patient age was 31.29±9.56 years. 64.7% (n=11) 
patients were female and 35.3% (n=6) male. 52.95% 
(n=9) patients had secondary and the rest had primary 
dengue infection based on dengue serology. 11.76% 
Figure1: Modified treatment algorithm for DSS patients 
Tachycardia/non palpable pulses
Pulse pressure <20 mm Hg to un recordable BP
UOP=<0.25 ml/kg/hr
Hematocrit (HCT) > 40 Hematocrit (HCT) < 40
Dextran or Starch 10ml/kg I/V over 60 min Packed cells/RCC 10ml/kg I/V over 60 min
Reassess for improvement (pulse pressure and urine output)
Improvement (pulse pressure 
>20mmHg)
Repeat HCT
HCT >40
HCT <40
Continue RCC** over 2 -6 
hours  in tapering manner*
Continue Dextran/ Starch over 2 -6 
hours in tapering manner*
No improvement/Static condition (pulse pressure<20mm 
 Infuse 
RCC**/Dextran/Starch 
depending on HCT
 Use Dopamine as 
vasopressor agent
 Use Dobutamine in 
cardiac dysfunction 
 Dobutamine  can be used 
in combination with 
dopamine if 
hemodynamics cannot be 
achieved with -Dopamine 
alone
Remain improved: continueHCT and 
hemodynamics monitoring, switch to 
crystalloid
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Table I. Group wise characteristics 
 Recovered 
(n=13) 
Expired 
(n=4) 
p- 
value 
Mean age (years) 30.69±9.12 33.25±12.17 >0.05 
Female 61.54% (n=8) 75% (n=3) >0.05 
Male 38.46% (n=5) 25% (n=1)  
Primary dengue 
infection 
53.84% (n=7) 25%  (n=1) >0.05 
Secondary 
dengue infection 
46.15% (n=6) 75%  (n=3)  
Additional 
illness present 
15.38% (n=2) 75% (n=3) 0.02 
Mean duration of 
hospital stay* 
5.92±2.06 3±2 0.02 
*Days. 
 (n=2) patients were NS1 positive, 35.29% (n=6) were 
NS1 and IgM positive, 29.41% (n=5) were NS1 and IgG 
positive, 17.64% (n=3) were NS1, 
IgM, and IgG positive, and 5.88% 
(n=1) IgM and IgG positive. 
Extravascular volume overload 
(EVO) when actually patients had 
intravascular volume depletion was 
noted in all patients. It was 
diagnosed when patients had puffy 
face, tachypnea, shortness of breath, 
bilateral crackles/wheeze, neck vein 
distension, and increasing ascites/ 
pleural effusion/ pedal edema.9,15,16 
Mean duration of hospital stay was 
5.23±2.35 days.29.41% (n=5) patients 
had additional illness/co morbidity, 
while the rest did not have. These 
included rheumatoid arthritis, 
urinary tract infection, diabetes 
mellitus, hypertension, and 
combination of urinary tract 
infection, sepsis and eclampsia. 
76.47% (n=13) patients recovered 
and were discharged. 23.52% (n=4) 
patients died.27.27% (n=3) females 
and 16.66% (n=1) male were among 
deceased.Statistically significant association was noted 
in terms of presence or absence of additional illnesses 
and duration of hospital stay in this group wise 
comparison (Table 1). 
 
Discussion 
Important points to be considered about our study are; 
1) patients included in this study suffered from DSS 
and decompensated shock/circulatory failure, 2) they 
did not improve with DEAG guidelines based 
management for this category of patients, 3) study 
focused adult patients, 4) all patients had features 
suggestive of EVO, and 5) modification of DEAG 
management algorithm for decompensated shock lead 
to recovery in 76.47% patients. 
DEAG guidelines for dengue management are based 
on similar work up from South Asian countries like Sri 
Lanka and Thailand. According to these, for 
management of decompensated shock patients 20 
ml/Kg normal saline bolus is administered. Those 
who do not improve receive another bolus of 5 ml/Kg 
normal saline. HCT is checked in non-responders and 
they are categorized to two groups. First group whose 
HCT decreases >10 units are transfused fresh blood, 
second with <10 unit change in HCT are administered 
10 ml/Kg bolus of colloid. Algorithm suggests blood 
transfusion for further management of first group. Of 
the second group patients who improve are switched 
to crystalloid 1.5-10 ml/Kg/hour. Those who do not 
improve have their HCT rechecked and treatment is 
administered based on the two groups. Figure II give 
details in this regard. 
According to WHO guidelines for clinical 
management of dengue decompensated shock patients 
should receive 20 ml/Kg bolus of colloid- preferably- 
or crystalloid. Patients who do not improve are 
reviewed with HCT and are categorized on the basis 
of their HCT into those who have fall in HCT and with 
higher than baseline or age, gender standardized HCT. 
Figure 2: Fluid management in decompensated shock 
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Patients with HCT on higher side are managed with 
10-20 ml/Kg bolus of colloid which is reduced to 7-10 
ml/Kg in next 1-2 hour and then subsequently 
changed with crystalloid in tapering way if condition 
improves. Adult male whose HCT is <40-45 and 
females with HCT <35-40 are treated with fresh whole 
or packed cell transfusion if there is bleeding, 
otherwise 10-20 ml/Kg bolus of colloid is 
administered. Algorithm in this regard is given in 
Figure III.5 
Based on our experience of managing DHF/DSS 
patients we had noted that patients who improve with 
colloid or blood administration again go into 
decompensated shock when switch over to crystalloid 
solution is done. Continuing with colloid or blood 
depending on HCT in tapering way for next few hours 
followed by switching to crystalloid solution lead to 
smooth recovery in these patients. This along with 
WHO guideline based management was the basis of 
DEAG algorithm modification. 
Although all of our patients did not improve with our 
management plan however, it is clear that if such 
modifications were not employed mortality could have 
been much higher. Interestingly, algorithm similar 
somewhat to ours, have been advocated for dengue 
patient management.6 Ours are however more detailed 
and were tested on adult patients in epidemic settings.  
Dengue related mortality is 1-2%.7,8,9 Fatality rates in 
hospitalized dengue patients which used be 20% has 
reduced to 0.5-2% recently.10 DHF related mortality is 
5%.11 1-30% mortality has been 
generally described in DSS 
patients.12,13 
It can however increase up to 
44%.8,9It is important to note 
that children constitute 
majority of patients rather than 
adults in these analysis. 
Comparatively high (5.5%) case 
fatality rate has been noted in 
adults with DSS.14Higher 
mortality (30%) has been noted 
in patients who have shown 
poor response to standard DSS 
management.13Mortality in our 
patients (23.52%) seems 
comparably high but it should 
be noted that if we would not 
have modified the treatment 
algorithm higher mortality 
could have resulted.   
Interestingly all our patients 
had features of EVO, which in 
settings of dengue generally 
results from excessive fluid 
intake by the patient or 
overzealous fluid 
administration by treating 
persons.21 This finding in all of 
our patients indicates 
complexity of situation as all of them were not 
responding to routine treatment protocols. EVO occurs 
either in later part of critical period or after it is over.21 
It should be managed using the strategy employed by 
us. 
Comparing characteristic of our patients with other 
studies is difficult as our patient cohort consisted of 
critically ill adult DSS patients. In a somewhat related 
study focusing critically ill DSS patients 53.7% patients 
were female, 51.85% patients were >21 years old, and 
16 out of 54 patients expired of which 10 were ≤20 
years old.13 We noted somewhat similar results.   
DHF/DSS are commonly considered as sequel of 
secondary dengue infection. Primary dengue infection 
has also been associated with DHF/DSS however. 
Figure 3: Algorithm for fluid management in hypotensive shock 
Journal of Rawalpindi Medical College (JRMC); 2016;20(1):2-6 
 6 
Primary dengue infection has been noted in fatal DHF 
patients.17 It was frequently noted in our patients as 
well. Additional illnesses/co morbidities association 
with DHF/DSS has been variable in various 
sstudies.18,19,2042.87% of fatal DHF cases in a study 
from Singapore had additional illneses.17Additional 
illnesses/co morbidities were significantly more in our 
patients who expired compared to who improved 
(75%:15.38%). 
1-8 days duration of ICU stay was noted in a study 
focusing critically ill DSS patients.13 In a study which 
focused risk factors for death in admitted dengue 
patients it was noted that patients who expired had 
longer duration of hospitalization. Our results are 
different in this regard.20 Our patients who expired 
had significantly shorter duration of hospitalization. 
Conclusion 
DSS patients who did not improve with DEAG 
guideline based treatment in our study had 
extravascular volume overload. Simple modification in 
DEAG treatment plan that entails continuing with 
colloid or blood depending on HCT in tapering way 
for initial few hours after hemodynamic stabilization is 
achieved lead to improvement in majority of patients. 
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